Rhumbline Advisers purchased a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 12,353 shares of the company's stock, valued at approximately $320,000.
CeriBell Price Performance
CBLL stock traded down $0.10 during mid-day trading on Wednesday, hitting $23.13. 2,149 shares of the company were exchanged, compared to its average volume of 201,368. CeriBell has a 12-month low of $18.69 and a 12-month high of $32.75. The firm's fifty day simple moving average is $22.85.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million for the quarter, compared to analysts' expectations of $17.55 million. Sell-side analysts anticipate that CeriBell will post -2.46 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on CBLL shares. Canaccord Genuity Group restated a "buy" rating and set a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. TD Cowen lifted their price target on shares of CeriBell from $31.00 to $36.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, CeriBell presently has a consensus rating of "Buy" and an average target price of $32.60.
Get Our Latest Stock Analysis on CeriBell
CeriBell Profile
(
Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Further Reading
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
